ACOG Alpha Cognition: Multiplikator Forward P/S
Alpha Cognition develops innovative treatments for Alzheimer's, targeting the global neurology sector. A complex certification process and patents protect its developments from replication, while critical demand enables the company to maintain pricing power. This forward price-to-sales valuation chart from GURU.Markets visualizes the volatility of market expectations, where 9.30 serves as the final level marker.
Rincian analitis perusahaan alphacognition.com (ACOG)
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- rincian utang lan likuiditas:
Rasio Total Utang marang Ekuitas Alpha Cognition|ACOG - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Alpha Cognition Inc.|ACOG - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Alpha Cognition Inc.|ACOG - Utang jangka dawa|Utang jangka cendhak perusahaan Alpha Cognition|Rasio cepet alphacognition.com
- data bathi bisnis lan rasio investasi:
ACOG - Bathi resik|Proyeksi bathi mangsa ngarep Alpha Cognition|ACOG - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Alpha Cognition Inc.|ACOG - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Alpha Cognition Inc.|ACOG - Bathi operasional sadurunge potongan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Alpha Cognition|ACOG - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan alphacognition.com|ACOG - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Alpha Cognition
- indikator dodolan lan pendapatan:
Analisis komprehensif perusahaan:ACOG (Alpha Cognition Corp)
For Alpha Cognition (ACOG), which possesses significant pricing power due to the unique delivery method of the drug Zunveyl, this indicator reflects the ratio of current market capitalization to expected future sales volume. Analyzing the forward revenue multiple allows investors to efficiently assess business value between quarterly reports, mitigating the risk of missing the entry point and protecting capital from sharp drawdowns amid inelastic demand.
Analisis pesaing
Rasio rega marang prakiraan pendapatan Biogen BIIB|Neurocrine (NBIX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Regencell - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Axsome Corp (AXSM)|ACADIA Pharmaceuticals (ACAD) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan XENE|VKTX (Viking Therapeutics, Inc.) - Multiplikator Forward P/S|Supernus Pharmaceuticals, Inc. (SUPN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CPRX (Catalyst Pharmaceuticals Inc)|Rasio rega marang pendapatan sing dikarepake DNLI|Multiplikator Forward P/S HRMY (Harmony Biosciences)|Rasio kapitalisasi marang dodolan sing dikarepake biohavenpharma.com (BHVN)|AMLX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Trevi Therapeutics Inc|Praxis Medicines (PRAX) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan AVXL|CBLL (CeriBell, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Prothena Corporation|Multiplikator Forward P/S ALEC|Multiplikator forward rega marang pendapatan Annexon Biosciences ANNX|Rasio rega marang prakiraan pendapatan Omeros OMER|Neurogene Therapeutics (NGNE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AC Immune - Multiplikator Forward P/S|Prakiraan rega marang pendapatan voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. (NMRA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan SCLX|TVGN (Tevogen Bio Holdings, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cognition Therapeutics Inc. CGTX|Multiplikator forward rega marang pendapatan IKT (Inhibikase Therapeutics)|Multiplikator Forward P/S cassavasciences.com (SAVA)|Rasio rega marang prakiraan pendapatan Assertio ASRT|Rega forward marang dodolan COYA|VTGN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ovid Therapeutics Inc.|ABOS: Multiplikator Forward P/S|cervomed.com (CRVO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Ltd.|Rasio rega marang prakiraan pendapatan CLNN|Rasio rega marang prakiraan pendapatan PepGen Inc. (PEPG)|JUNS: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S RLMD (Relmada Therapeutics)|Rega forward marang dodolan ANVS|Grace Tx - Multiplikator Forward P/S|AIFF - Multiplikator Forward P/S|KLTO (anewmeds.com) - Multiplikator forward rega marang pendapatan|NeuroSense Therapeutics Ltd. - Rega forward marang dodolan|RVPH (Reviva Pharmaceuticals) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan MetaVia, Inc. (MTVA)|Rasio rega marang prakiraan pendapatan NeurAxis (NRXS)|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S PASG (Passage Bio)|Prakiraan rega marang pendapatan Neuphoria Therapeutics, Inc.|NERV - Rasio rega marang prakiraan pendapatan|ATHA (athira.com) - Kapitalisasi marang prakiraan pendapatan|ADXN: Multiplikator Forward P/S|ALZN - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CYCN|PTIX (Protagenic) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake cortigent.com|Rasio rega marang prakiraan pendapatan Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. (BCLI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CARA - Rasio rega marang prakiraan pendapatan|CHRO (Chromocell) - Kapitalisasi marang prakiraan pendapatan|ELYM: Multiplikator Forward P/S|Intra-Cellular Therapies, Inc. (ITCI) - Multiplikator Forward P/S|LBPH (Longboard Pharmaceuticals, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Marinus Pharmaceuticals Inc (MRNS)|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|NRBO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S SAGE (Sage Therapeutics, Inc.)|Prakiraan rega marang pendapatan synaptogen.com|TRVN - Rasio rega marang prakiraan pendapatan|VIGL (Vigil Neuroscience) - Kapitalisasi marang prakiraan pendapatan|WENA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cerevel Corp (CERE)
